🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 5 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 12/09/2011 | 45,01 | 47,79 | 44,95 | 47,78 | +4,30% | 6,31% | 2.098.400 |
| 09/09/2011 | 47,02 | 47,27 | 45,25 | 45,81 | -3,70% | 4,30% | 2.202.600 |
| 08/09/2011 | 46,43 | 48,26 | 46,00 | 47,57 | +1,34% | 4,87% | 2.253.900 |
| 07/09/2011 | 46,33 | 46,98 | 45,94 | 46,94 | +3,01% | 2,24% | 1.274.900 |
| 06/09/2011 | 43,67 | 45,87 | 43,25 | 45,57 | +2,20% | 6,00% | 2.765.300 |
| 02/09/2011 | 44,29 | 45,83 | 44,15 | 44,59 | -1,15% | 3,79% | 1.275.000 |
| 01/09/2011 | 45,59 | 46,34 | 44,80 | 45,11 | -0,35% | 3,38% | 1.176.700 |
| 31/08/2011 | 45,43 | 46,67 | 45,02 | 45,27 | +0,00% | 3,63% | 1.420.800 |
| 30/08/2011 | 44,39 | 45,63 | 43,82 | 45,27 | +3,00% | 4,08% | 1.736.600 |
| 29/08/2011 | 45,00 | 45,33 | 43,66 | 43,95 | -2,89% | 3,71% | 2.959.200 |
| 26/08/2011 | 45,04 | 45,90 | 43,34 | 45,26 | -0,33% | 5,68% | 2.441.500 |
| 25/08/2011 | 46,74 | 47,20 | 45,30 | 45,41 | -2,41% | 4,07% | 991.900 |
| 24/08/2011 | 46,94 | 47,15 | 45,22 | 46,53 | -0,96% | 4,11% | 1.271.600 |
| 23/08/2011 | 45,64 | 47,00 | 44,45 | 46,98 | +3,30% | 5,59% | 1.405.700 |
| 22/08/2011 | 47,53 | 47,53 | 44,63 | 45,48 | -2,17% | 6,10% | 1.676.200 |
| 19/08/2011 | 44,68 | 47,90 | 44,53 | 46,49 | +2,65% | 7,54% | 2.279.800 |
| 18/08/2011 | 45,68 | 46,11 | 44,55 | 45,29 | -2,92% | 3,42% | 2.068.300 |
| 17/08/2011 | 46,76 | 47,81 | 45,80 | 46,65 | +1,06% | 4,30% | 1.668.100 |
| 16/08/2011 | 45,98 | 46,47 | 45,19 | 46,16 | -0,32% | 2,78% | 1.703.500 |
| 15/08/2011 | 44,72 | 46,33 | 44,49 | 46,31 | +4,09% | 4,11% | 1.668.300 |
| 12/08/2011 | 42,72 | 45,15 | 42,72 | 44,49 | +2,58% | 5,69% | 1.819.600 |
| 11/08/2011 | 41,89 | 44,00 | 41,31 | 43,37 | +3,81% | 6,42% | 1.603.900 |
| 10/08/2011 | 42,45 | 44,36 | 41,75 | 41,78 | -6,01% | 6,15% | 2.604.300 |
| 09/08/2011 | 40,64 | 44,47 | 40,05 | 44,45 | +11,13% | 10,88% | 4.292.300 |
| 08/08/2011 | 41,96 | 42,34 | 39,06 | 40,00 | -6,98% | 7,82% | 4.893.900 |
| 05/08/2011 | 44,18 | 46,70 | 41,48 | 43,00 | -2,69% | 11,82% | 3.746.200 |
| 04/08/2011 | 47,08 | 47,38 | 43,86 | 44,19 | -7,75% | 7,48% | 2.980.700 |
| 03/08/2011 | 48,90 | 49,00 | 46,50 | 47,90 | -2,34% | 5,11% | 1.793.700 |
| 02/08/2011 | 50,73 | 51,44 | 48,96 | 49,05 | -3,71% | 4,89% | 2.175.900 |
| 01/08/2011 | 52,39 | 53,00 | 50,15 | 50,94 | -1,77% | 5,44% | 2.116.400 |